Clinical Trial

Bismuth Subsalicylate in Prevention of Travelers' Diarrhea

Study Description

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among international travelers who departed from the United States to South East Asia, South Central Asia, or Africa. Our hypotheses will be tested using a double-blinded, placebo controlled randomized clinical trial with participants from a pre-travel health clinic in the United States.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Bismuth subsalicylate

We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.

Drug - Placebo Oral Tablet

Placebo manufactured to mimic pepto bismol

Additional Information

Official Study Title

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea and Impact on Acquisition of Gut Antimicrobial Resistance Genes

Clinical Trial ID

NCT03535272

ParticipAid ID

YerQ2d